Jason Damiano

Company: Appia Bio

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: Evaluating Safety & CMC Expectations between Different Cell Therapy Types & Autoimmune Indications

Moderator – Fred Aslan, Chief Executive Officer, Artiva Biotherapeutics 8:30 am

• Discussing the advantages and disadvantages of different cell therapy modalities when meeting CMC expectations • Understanding safety parameters that need to be demonstrated and how those may differ in various autoimmune indications • What are some of the standards that are set or need to be set for cell therapies to advance in the…Read more

day: Day Two AM

Engineered Stem Cell Derived NKT & Gamma Delta T-cell Therapies: Scalable Products with Enhanced Safety for Autoimmune Diseases 1:30 pm

• Highlighting strong efficacy and depth of B-cell depletion, comparable to CAR-T cells in preclinical models • Discussing modifications of NKT and gamma delta T-cells for reduced risk of adverse events such as CRS and ICANS • Elucidating key market advantages of NKT cells, such as scalable manufacturing and off-the-shelf availabilityRead more

day: Day One Track A, PM